Chester County News and Community Website
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) unveiled significant progress in its efforts to combat neurodegenerative diseases with updates on its pivotal Phase 3 clinical trial and solid financial …
Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress Read More
PHILADELPHIA, PA — The Global CEO Initiative on Alzheimer’s Disease (CEOi) has unveiled an innovative Alzheimer’s Blood Test Performance Database, providing a much-needed tool to help healthcare professionals evaluate and compare …
Global CEO Initiative Launches Alzheimer’s Blood Test Performance Database Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS), a clinical-stage biopharmaceutical company, is set to showcase significant advancements in its treatments for Alzheimer’s disease (AD) and Parkinson’s disease (PD) at the …
Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) will hold a live webcast aimed at providing patients, caregivers, and families with updates on its clinical trials and future plans. The virtual …
Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has initiated its pivotal Phase 3 clinical trial evaluating buntanetap as a treatment for early Alzheimer’s disease (AD), marking an important step forward …
Annovis Bio Launches Phase 3 Trial for Alzheimer’s Drug Buntanetap Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced that the U.S. Food and Drug Administration (FDA) has accepted an updated protocol for the company’s pivotal Phase 3 Alzheimer’s (AD) …
FDA Accepts Revised Protocol for Annovis Bio’s Phase 3 Alzheimer’s Study Read More
SPRINGFIELD, PA — Springfield, Pa.-based SageLife has raised and donated more than $50,000 to support the Alzheimer’s Association Delaware Valley Chapter.
SageLife Contributes $50,000 to Support Alzheimer’s Association Delaware Valley Chapter Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced its financial results for the third quarter ending September 30, 2024, alongside significant progress in its Alzheimer’s treatment pipeline.
Annovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial Updates Read More
AUSTIN, TX, and MALVERN, PA — In a promising development for Alzheimer’s disease diagnostics, Veravas, Inc. and Phanes Biotech have announced their collaboration to create a blood-based test for detecting …
Veravas and Phanes Biotech Collaborate to Innovate Alzheimer’s Disease Testing Read More
HARRISBURG, PA — The Pennsylvania Department of Aging (PDA) held its annual virtual forum on Thursday, drawing 488 attendees to a comprehensive discussion on brain health and community support. This …
Pennsylvania Department of Aging Hosts Virtual Forum to Tackle Alzheimer’s and Related Disorders Read More